Equities Analysts Set Expectations for DMAC Q1 Earnings

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for DiaMedica Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst M. Caufield expects that the company will post earnings of ($0.18) per share for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for DiaMedica Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.93) EPS, FY2027 earnings at ($0.92) EPS, FY2028 earnings at ($0.46) EPS and FY2029 earnings at $0.06 EPS.

DiaMedica Therapeutics (NASDAQ:DMAC) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01).

DiaMedica Therapeutics Trading Down 1.9 %

Shares of DMAC stock opened at $5.14 on Friday. The business’s fifty day simple moving average is $5.94 and its 200-day simple moving average is $5.10. The company has a market cap of $219.79 million, a PE ratio of -9.18 and a beta of 1.52. DiaMedica Therapeutics has a 12-month low of $2.14 and a 12-month high of $6.82.

Hedge Funds Weigh In On DiaMedica Therapeutics

Large investors have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of DiaMedica Therapeutics during the third quarter worth $40,000. Balyasny Asset Management L.P. acquired a new position in shares of DiaMedica Therapeutics during the fourth quarter worth $79,000. Y Intercept Hong Kong Ltd acquired a new position in shares of DiaMedica Therapeutics during the fourth quarter worth $81,000. Raymond James Financial Inc. acquired a new position in shares of DiaMedica Therapeutics during the fourth quarter worth $83,000. Finally, Bank of Montreal Can acquired a new position in shares of DiaMedica Therapeutics during the fourth quarter worth $84,000. 10.12% of the stock is owned by institutional investors and hedge funds.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.